1 / 33

Vascular & Interventional Radiology Unit Department of Radiological Sciences

N EW TECHNOLOGIES: Wires, balloons, drug-eluting devices, ect . Fabrizio Fanelli . Vascular & Interventional Radiology Unit Department of Radiological Sciences “ Sapienza” – University of Rome. Below The Knee Arteries. Small vessels Long lesions Occlusions > stenoses

uriel
Télécharger la présentation

Vascular & Interventional Radiology Unit Department of Radiological Sciences

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NEW TECHNOLOGIES: Wires, balloons, drug-eluting devices, ect. Fabrizio Fanelli Vascular & InterventionalRadiologyUnit DepartmentofRadiologicalSciences “Sapienza” – UniversityofRome

  2. Below The KneeArteries • Small vessels • Long lesions • Occlusions > stenoses • More vessels • Calcifications L. Graziani – Eur J VascEndovascSurg 2007

  3. CLI : MeanLengthTreatedlesions 5% ATG 63±61 mm 55% FEM-POP 116±113 mm 185±121 mm 96% BTK R.Ferraresi - oralpresentation CICE 2012

  4. 1) F. Liistro- oralpresentationTCT 2012 4) K. Katsanos- oralpresentationCIRSE 2011 2) A. Schmidt – JACC 2011 5) M. Bosiers – J VascSurg 2012 3) F. Fanelli - oralpresentationCIRSE2012 6) A. Rastan – EuropeanHeart Journal 2011

  5. …. New Technologies ….

  6. Micro-puncture set • Guidewires • Micro-guidewires • Introducers • Supportcatheters • Low profile balloon catheters • Atherectomydevices • Drugelutingballoons (DEB) • Bare metal stents • Drugelutingstents (DES)

  7. Micro-puncture set • Guidewires • Micro-guidewires • Introducers • Supportcatheters • Low profile balloon catheters • Atherectomydevices • Drugelutingballoons (DEB) • Bare metal stents • Drugelutingstents (DES)

  8. DrugElutingBalloons • In.PactAmphirion– Medtronic/Invatec • Advance LP 18 PTX – Cook • Freeway II/Dior – Eurocor • Elutax – AachenMedical

  9. DEB BTK LeipzigRegistry IN.PACT™Amphirion in real world BTK complexlesions A. Schmidt – JACC 2011

  10. vs historical PTA cohort(A.Schmidt - Cath. and Cardiovasc. Interventions 2010) DEB BTK LeipzigRegistry (1) clinical improvement = reduction in size and/or depth of ulceration or improvement of rest-pain

  11. vs historical PTA cohort(A.Schmidt - Cath. and Cardiovasc. Interventions 2010) DEB BTK LeipzigRegistry (1) clinical improvement = reduction in size and/or depth of ulceration or improvement of rest-pain

  12. DEBATE BTK • Investigator initiated, single center Study • Randomized (1:1) DEB vs. standard PTA • Primary Endpoint: 12-month Angiographic • Binary (>50%) Restenosis Rate • Secondary Endpoints: TLR and Reocclusion CLI + Diabetes 150 (Tibial) Lesions Random(1:1) DEB (75 lesions) Std PTA (75 lesions) • Key Inclusions • RC 4-5-6 and Diabetes • Stenosis / occlusions >40 mm in at least 1 tibial vessel with distal run-off • Key Exclusions • Allergy to Paclitaxel • Contraindication for combined antiplatelet treatment • Life expectancy <1 year Aspirin + Clopidogrel (1 month) 12-month Angiographic and Clinical follow-up 24-month Duplex and Clinical follow-up F. Liistro- oralpresentationTCT 2012

  13. DEBELLUM DrugEluting Balloon EvaluationforLowerLimbmUltileveltreatMent • Investigator initiated, single center Study • Randomized (1:1) DEB vs. standard PTA • Primary Endpoint: 6-month LLL • Secondary Endpoints: TLR, Primary Patency, Fontaine change, MAE at 6 and 12 months • Key Inclusions • Fontaine Stage IIb, III, IV • SFA, popliteal and BTK lesions either isolated or concomitant • De-novo lesions • Stenosis or occlusions 3 - 30 cm F. Fanelli - oralpresentationCIRSE2012

  14. 12-mos TLR analysis per lesion

  15. DEBELLUM- 12 mos F.U.

  16. ProspectiveRandomizedMulticenter Trial • 50 pts. • RC: 4-6 • >50% calcifiedstenosis • popliteal, tibial and peronealaa.

  17. SecondaryEndpoints

  18. 1) F. Liistro- oralpresentationTCT 2012 2) A. Schmidt – JACC 2011 3) F. Fanelli - oralpresentationCIRSE2012

  19. WhataboutStent… ?

  20. 1) F. Liistro- oralpresentationTCT 2012 4) K. Katsanos- oralpresentationCIRSE 2011 2) A. Schmidt – JACC 2011 5) M. Bosiers – J VascSurg 2012 3) F. Fanelli - oralpresentationCIRSE2012 6) A. Rastan – EuropeanHeart Journal 2011

  21. 1) F. Liistro- oralpresentationTCT 2012 4) K. Katsanos- oralpresentationCIRSE 2011 2) A. Schmidt – JACC 2011 5) M. Bosiers – J VascSurg 2012 3) F. Fanelli - oralpresentationCIRSE2012 6) A. Rastan – EuropeanHeart Journal 2011

  22. JVIR 2009; 20(9):1141-1150 Everolimus-elutingstent vs. bare metal stent 103 pts. CLI Angioplasty + Bailoutstenting

  23. HR: 4.8, CI 2.9-7.9 p<0.001 HR: 2.5, CI 1.3-5.0 p=0.006 D. Siablis – JVIR 2009; 20(9):1141-1150

  24. Xcience-Prime Xcience-Prime

  25. Conclusions • DEB patency rate similarto DES butwith the advantageof • “nothingleftbehind”. • Efficacyof DEB in verycalcifiedarteriesstill under evaluation • Combined treatment withatherectomymustbevalidated.

  26. The Future … BioabsorbableStent • Adaptiontoflexion, extension • •OvercomeStentfractures • •PositiveRemodelling • •Might act as a transporter (Gen-Therapy) • •Surgeon’s friend

  27. ABSORB Study Poly-L-lactide + Everolimus 30 pts. 5-y F.U. - No cardiacdeath - No thrombosis - MACE: 3.4 % - LLL 0.27 mm

  28. fabrizio.fanelli@uniroma1.it

More Related